Regulatory Failures and the Opioid Crisis

This chapter examines the FDA's contentious relationship with the pharmaceutical industry and its role in the opioid crisis. It highlights regulatory failures, particularly in the approval processes for drugs like OxyContin and MS-Contin, and discusses the implications of prioritizing rapid access to medications over safety. The narrative emphasizes the need for a more stringent application of scientific evidence in drug approvals to prevent future public health disasters.